Roche Signs Definitive Agreement To Acquire Telavant Holdings

Roche has announced the signing of a formal agreement to purchase Telavant Holdings, Inc. (Telavant), a Roivant firm owned by Roivant Sciences Ltd. and Pfizer Inc. Televant's RVT-3101, a unique TL1A directed antibody, will be developed, manufactured, and commercialized in the United States and Japan under the terms of the agreement. RVT-3101 is a potential novel medication under development for persons with inflammatory bowel disease, such as ulcerative colitis.

Roche has announced the signing of a formal agreement to purchase Telavant Holdings, Inc. (Telavant), a Roivant firm owned by Roivant Sciences Ltd. and Pfizer Inc. Televant's RVT-3101, a unique TL1A directed antibody, will be developed, manufactured, and commercialized in the United States and Japan under the terms of the agreement. RVT-3101 is a potential novel treatment under development for persons with inflammatory bowel illness, such as ulcerative colitis and Crowns’ disease. Inflammatory bowel disease is a collection of chronic gastrointestinal illnesses that affect almost 8 million people globally, with 80% of patients not experiencing long-term remission. Because of the antibody's new method of action, which targets both inflammation and fibrosis, it has the potential to be used in a variety of additional disorders,as per pharmabiz.

In the TUSCANY-2 phase 2b research, RVT-3101 was tested in individuals with moderate to severe ulcerative colitis. The worldwide, randomized, double-blind, placebo-controlled study provided the first long-term dose-finding data from a significant number of patients (n=245). Following induction, the maintenance therapy phase resulted in increased clinical remission (36% at week 56) and endoscopic improvement (50% at week 56) at the recommended phase 3 dosage delivered subcutaneously once a month. Aside from the effectiveness results, the RVT-3101 maintenance dosage period demonstrated a favorable safety profile across all patients.